Developer docs
API playgroundTry for free, no card

Search company profiles

Encoded Therapeutics

Full company profile

uuid00007zl

Namestring
Encoded Therapeutics
Legal namestring
Encoded Therapeutics, Inc.
Websiteurl
encoded.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Encoded Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California, with a secondary Research Triangle Park facility in Morrisville, North Carolina. The company develops one-time, AAV-based gene regulation therapies for severe neurological disorders, with a lead clinical program ETX101 for SCN1A+ Dravet syndrome delivered as a single intracerebroventricular infusion. Its core technology is the Genetic Medicines Product Engine, a proprietary platform that combines high-throughput next-generation sequencing (NGS) screening of human regulatory elements (promoters, enhancers, 3'UTRs) with machine learning to design cell-type-selective AAV cassettes, including REGABA (GABAergic interneuron-selective), NociPro (nociceptor-selective), and DRG de-targeting 3'UTR elements. Encoded also operates an internal GMP manufacturing ecosystem supplemented by preferred CDMO relationships, and pairs its in-house vector engineering with externally licensed BBB-crossing AAV variants where appropriate. Beyond ETX101, the pipeline includes ETX301 (preclinical AAV9-miRNA targeting SCN9A/NaV1.7 in dorsal root ganglion nociceptors for post-amputation neuroma pain), an Angelman syndrome UBE3A-unsilencing program, and an Alzheimer's/tauopathies MAPT-knockdown program.

Encoded is pre-revenue and does not currently offer pre-approval access anywhere in the world; its long-term revenue model is expected to be one-time, single-administration gene therapy product sales (with possible partnering income from co-development and licensing). Current go-to-market is exclusively via clinical trial distribution at specialized centers of excellence in the US (ENDEAVOR), UK (EXPEDITION), and Australia (WAYFINDER), supported by Medical Affairs outreach to healthcare professionals, a Patient Advocacy team engaged with the Dravet, Angelman, and broader pediatric CNS communities, and a Business Development channel for inbound partnering inquiries. The company has raised approximately $239M in disclosed venture funding (Series C of $104M in June 2019 and Series D of $135M in July 2020) from investors including ARCH Venture Partners, Venrock, Matrix Capital, SoftBank Vision Fund, GV, Illumina Ventures, Alexandria, Boxer Capital, Menlo Ventures, RTW, and others; no subsequent financing round is disclosed.

Short descriptiontext

Encoded Therapeutics is a clinical-stage biotechnology company developing one-time AAV-based gene regulation therapies for severe neurological disorders, with lead program ETX101 in pivotal trials for SCN1A+ Dravet syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, neurological disease treatment, precision genetic medicines, regulatory genome platform, cell-selective gene regulation
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene therapy for neurological disorders
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Future one-time gene therapy product sales
TypeOne Time License
Description

Encoded is a clinical-stage biotechnology company with no products currently approved or generating revenue. ETX101, ETX301 and pipeline programs are investigational. The expected long-term revenue model is one-time (single-administration) sales of AAV gene therapy products targeting monogenic and common neurological disorders. Encoded does not currently offer pre-approval access anywhere in the world. Future revenue may also include partnering income from co-development and licensing opportunities.

encoded.com
Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Investigational one-time gene therapy — pricing not publicly disclosed
ModelOne time/ perpetual license
Notes

No pricing disclosed. Encoded states that providing early access can involve unknown risks, may undermine trial completion needed for regulatory approval, and as such does not currently offer pre-approval access anywhere in the world.

encoded.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Encoded Therapeutics is a clinical-stage biotechnology company developing one-time, AAV-based precision gene therapies that target the underlying genetic cause of severe neurological disorders. Its proprietary Genetic Medicines Product Engine uses high-throughput NGS screening of human regulatory elements combined with machine learning to design cell-selective cassettes (e.g., REGABA promoter, NociPro promoter, DRG de-targeting 3'UTRs) delivered via clinically validated AAV9 capsids. The lead investigational product, ETX101, is in pivotal development for SCN1A+ Dravet syndrome with five FDA designations (Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug) plus EMA Orphan designation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • ~76% median monthly countable seizure frequency (MCSF) reduction at DL3 (n=3) sustained from Week 5 through Week 52
+6 more records
Product overview1 text field

Encoded Therapeutics is a clinical-stage biotechnology company whose offering is organized as a single integrated R&D engine — the Genetic Medicines Product Engine — that generates and advances a wholly owned pipeline of one-time, precision AAV-based genetic medicines for severe neurological disorders. The platform combines high-throughput NGS screening with machine-learning-driven regulatory element optimization to engineer cell-type-selective AAV cassettes (e.g., REGABA for GABAergic neurons; NociPro for nociceptors; 3'UTR DRG de-targeting elements) and supports an internal GMP manufacturing ecosystem. The engine currently powers four named pipeline programs: the lead clinical-stage product ETX101 (AAV9 gene regulation therapy for SCN1A+ Dravet syndrome, advanced under the integrated POLARIS clinical program), the preclinical ETX301 (AAV9-miRNA for post-amputation neuroma pain, IND planned for 2027), a preclinical Angelman syndrome UBE3A-unsilencing program, and a preclinical Alzheimer's/tauopathies MAPT-knockdown program. Programs span monogenic (Dravet, Angelman) and common (chronic pain, tauopathies) neurological indications.

Product and service6 records
1ETX101 (for SCN1A+ Dravet Syndrome)
CategoryInvestigational AAV gene therapy product
Description

Investigational AAV9-based, cell-selective gene regulation therapy for SCN1A+ Dravet syndrome. Delivered as a single intracerebroventricular (ICV) infusion, ETX101 uses an engineered transcription factor (eTF) under the GABAergic-selective REGABA promoter to upregulate endogenous SCN1A expression in inhibitory interneurons, restoring NaV1.1 sodium channel density. Designed for infants and young children aged 6 months to less than 4 years (pivotal Part 2) and ages 4 to 18 (Part 1B expansion). FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EMA Orphan designation.

2ETX301 (for post-amputation neuroma pain)
CategoryPreclinical AAV gene therapy product
Description

Investigational AAV9-based vectorized microRNA (miRNA) gene therapy for chronic neuropathic pain caused by post-amputation neuroma. Delivered via a single intrathecal injection using the NociPro nociceptor-selective promoter to knock down SCN9A (NaV1.7) in dorsal root ganglion nociceptive neurons. Targets the estimated 100,000 US patients with painful neuromas following lower limb amputation (~5,000 new cases annually). IND submission planned for 2027.

3Angelman Syndrome Program (UBE3A Unsilencing)
CategoryPreclinical AAV gene therapy program
Description

Preclinical one-time, vectorized miRNA-based gene therapy designed to unsilence the paternal UBE3A gene by targeting the UBE3A antisense transcript (UBE3A-ATS). Recent preclinical data showed ~57% increase in UBE3A expression and ~24% increase in UBE3A protein across cortex, hippocampus, and thalamus in non-human primates using a blood-brain-barrier-crossing AAV variant, with 60-day tolerability.

4Alzheimer's Disease / Tauopathies Program
CategoryPreclinical AAV gene therapy program
Description

Preclinical program applying Encoded's cell-selective AAV vector engineering to deliver miRNA-based knockdown of intracellular tau (MAPT), targeting Alzheimer's disease and related tauopathies. Addresses ~6 million people in the U.S. with Alzheimer's disease.

5Genetic Medicines Product Engine
CategoryInternal R&D and manufacturing platform
Description

End-to-end platform encompassing preclinical development, GMP manufacturing, multi-modal delivery, and clinical expertise for AAV-based gene therapies. Uses high-throughput NGS screening and machine-learning-driven regulatory element optimization to engineer cell-type-selective cassettes (REGABA for GABAergic neurons; NociPro for nociceptors; 3'UTR DRG de-targeting elements). Internal GMP manufacturing facility complemented by preferred CDMO relationships. Supports a wholly owned, internally developed pipeline of neurological gene therapies.

6POLARIS Clinical Program (ENDEAVOR, EXPEDITION, WAYFINDER, ENVISION)
CategoryIntegrated clinical development program for ETX101
Description

Comprehensive ETX101 clinical development program comprising Phase 1/2 dose-escalation studies (ENDEAVOR Parts 1A and 1B, EXPEDITION, WAYFINDER), pivotal ENDEAVOR Part 2 (NCT05419492), the ENVISION natural history study (NCT04537832), the Dravet ENGAGE patient-focused initiative, and the ELUCIDATE biomarker discovery program. Conducted across the United States, United Kingdom, and Australia under FDA, MHRA, and TGA oversight.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1External AAV capsid/BBB-crossing variant licensor (Angelman program)
Strategic tierResearch CollaborationTypeOEM/ Whitelabel/ Licensing Partner
Description

For the Angelman syndrome program, Encoded paired its optimized miRNA candidate with an externally-developed blood-brain-barrier-crossing AAV variant to achieve widespread miRNA expression across disease-relevant brain regions in non-human primates (~57% increase in UBE3A expression). The specific external licensor is not named in the source material.

encoded.com
2Preferred CDMO partners
Strategic tierOperational SupportTypeImplementation/ SI/ Consulting Partner
Description

Encoded's GMP manufacturing ecosystem includes preferred CDMO relationships to complement its in-house GMP manufacturing facility. Encoded has invested in its own manufacturing capabilities since inception, with process development meeting current AAV commercial-scale requirements and infrastructure that meets GMP-scale requirements for multiple programs.

encoded.com
3Industry co-development and licensing partners
Strategic tierFuture PotentialTypeStrategic or Co-development Partner
Description

Encoded states it aims to continue developing its pipeline utilizing end-to-end capabilities and leveraging its research platform to broaden therapeutic reach "independently as well as through industry partnerships". Company is actively evaluating co-development and licensing opportunities via partnering@encoded.com.

encoded.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in SCN1A+ Dravet syndrome. Stoke is developing STK-001, an antisense oligonucleotide that upregulates SCN1A expression — the same target as Encoded's ETX101 — using a different modality (ASO vs. AAV gene therapy). Stoke is the most clinically advanced competitor in Dravet syndrome and serves the same patient population and physician community.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing CNS-targeted genetic medicines. Notably, Encoded's Board Chairman Sean P. Nolan is also CEO of Taysha, creating direct leadership overlap. Both companies pursue AAV-based gene regulation therapies for severe neurological diseases with similar regulatory and manufacturing challenges.

TypeDirect peer
Description

AAV gene therapy company developing CNS-targeted treatments for neurodegenerative diseases. Encoded's CEO Kartik Ramamoorthi previously served on the team that launched Voyager. Both companies use AAV capsids to deliver gene regulation payloads to specific CNS cell types, and compete for similar scientific talent and clinical sites.

TypeBroad incumbent
Description

Established AAV gene therapy franchise within Novartis that developed and commercialized Zolgensma for spinal muscular atrophy — the benchmark one-time AAV therapy. Several Encoded executives (Sean Nolan, Andrew Stober) led AveXis through Zolgensma development, and AveXis represents the proven commercial and regulatory template for one-time AAV therapies in rare pediatric neurological disease.

TypeBroad incumbent
Description

AAV gene therapy unit of Astellas developing treatments for rare neuromuscular diseases (e.g., AT132 for X-linked myotubular myopathy). Encoded CMO Salvador Rico led AT132 clinical development at Audentes. Operates the same AAV gene therapy model — internal manufacturing, rare disease focus, complex regulatory pathway — though with some high-profile safety setbacks.

TypeBroad incumbent
Description

Established AAV gene therapy platform company that develops and licenses AAV capsid technology (including AAV9, used by Encoded for ETX101 and ETX301). Regenxbio is both a potential licensor/collaborator for Encoded and a competitor pursuing CNS and rare disease gene therapies using its proprietary NAV technology platform.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on Duchenne muscular dystrophy and CNS disorders. Similar to Encoded, Solid has faced safety setbacks, restructured operations, and rebuilt clinical programs — providing a comparable trajectory of a clinical-stage AAV gene therapy company navigating manufacturing scale-up and clinical development.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing CNS-targeted treatments for rare monogenic neurological diseases. Passage Bio's portfolio (e.g., GM1 gangliosidosis, Krabbe disease, frontotemporal dementia) overlaps with Encoded's CNS focus and shares similar scientific, manufacturing, and regulatory challenges in delivering AAV payloads to the brain.

TypeBroad incumbent
Description

Established gene therapy company with commercial AAV product (Hemgenix for hemophilia B) and CNS-directed AAV programs. Provides a comparable template for an AAV gene therapy company advancing from clinical development through commercial launch, including pricing, manufacturing, and reimbursement strategy for one-time therapies.

TypeBroad incumbent
Description

Large pharmaceutical company with a gene therapy portfolio that includes Beqvez (an AAV gene therapy for hemophilia B) and prior investments in AAV CNS programs. Represents a potential strategic acquirer or partner for Encoded's platform and pipeline, and a benchmark for large-pharma AAV manufacturing and commercialization capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Encoded Therapeutics

Gene therapy for neurological disordersencoded.com

Encoded Therapeutics is a clinical-stage biotechnology company developing one-time AAV-based gene regulation therapies for severe neurological disorders, with lead program ETX101 in pivotal trials for SCN1A+ Dravet syndrome.

What Encoded Therapeutics does

Encoded Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California, with a secondary Research Triangle Park facility in Morrisville, North Carolina. The company develops one-time, AAV-based gene regulation therapies for severe neurological disorders, with a lead clinical program ETX101 for SCN1A+ Dravet syndrome delivered as a single intracerebroventricular infusion. Its core technology is the Genetic Medicines Product Engine, a proprietary platform that combines high-throughput next-generation sequencing (NGS) screening of human regulatory elements (promoters, enhancers, 3'UTRs) with machine learning to design cell-type-selective AAV cassettes, including REGABA (GABAergic interneuron-selective), NociPro (nociceptor-selective), and DRG de-targeting 3'UTR elements. Encoded also operates an internal GMP manufacturing ecosystem supplemented by preferred CDMO relationships, and pairs its in-house vector engineering with externally licensed BBB-crossing AAV variants where appropriate. Beyond ETX101, the pipeline includes ETX301 (preclinical AAV9-miRNA targeting SCN9A/NaV1.7 in dorsal root ganglion nociceptors for post-amputation neuroma pain), an Angelman syndrome UBE3A-unsilencing program, and an Alzheimer's/tauopathies MAPT-knockdown program.

Encoded is pre-revenue and does not currently offer pre-approval access anywhere in the world; its long-term revenue model is expected to be one-time, single-administration gene therapy product sales (with possible partnering income from co-development and licensing). Current go-to-market is exclusively via clinical trial distribution at specialized centers of excellence in the US (ENDEAVOR), UK (EXPEDITION), and Australia (WAYFINDER), supported by Medical Affairs outreach to healthcare professionals, a Patient Advocacy team engaged with the Dravet, Angelman, and broader pediatric CNS communities, and a Business Development channel for inbound partnering inquiries. The company has raised approximately $239M in disclosed venture funding (Series C of $104M in June 2019 and Series D of $135M in July 2020) from investors including ARCH Venture Partners, Venrock, Matrix Capital, SoftBank Vision Fund, GV, Illumina Ventures, Alexandria, Boxer Capital, Menlo Ventures, RTW, and others; no subsequent financing round is disclosed.

Encoded Therapeutics firmographics

Firmographics
Name
Encoded Therapeutics
Legal name
Encoded Therapeutics, Inc.
Website
https://encoded.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Encoded Therapeutics is a clinical-stage biotechnology company developing one-time AAV-based gene regulation therapies for severe neurological disorders, with lead program ETX101 in pivotal trials for SCN1A+ Dravet syndrome.
Ownership category
akta.pro rank

Encoded Therapeutics industry classification

Industry
Product category
Gene therapy for neurological disorders
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Neurological disease treatment
  • Precision genetic medicines
  • Regulatory genome platform
  • Cell-selective gene regulation

Where Encoded Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Encoded Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pre-revenue / Future one-time gene therapy product sales: Encoded is a clinical-stage biotechnology company with no products currently approved or generating revenue. ETX101, ETX301 and pipeline programs are investigational. The expected long-term revenue model is one-time (single-administration) sales of AAV gene therapy products targeting monogenic and common neurological disorders. Encoded does not currently offer pre-approval access anywhere in the world. Future revenue may also include partnering income from co-development and licensing opportunities.

Pricing tiers

ModelBillingPrice
One time/ perpetual license—Investigational one-time gene therapy — pricing not publicly disclosed

Go-to-market motion3 records

Distribution channels4 records

Encoded Therapeutics product offering

Product offering

Core offering

Encoded Therapeutics is a clinical-stage biotechnology company developing one-time, AAV-based precision gene therapies that target the underlying genetic cause of severe neurological disorders. Its proprietary Genetic Medicines Product Engine uses high-throughput NGS screening of human regulatory elements combined with machine learning to design cell-selective cassettes (e.g., REGABA promoter, NociPro promoter, DRG de-targeting 3'UTRs) delivered via clinically validated AAV9 capsids. The lead investigational product, ETX101, is in pivotal development for SCN1A+ Dravet syndrome with five FDA designations (Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug) plus EMA Orphan designation.

Product overview

Encoded Therapeutics is a clinical-stage biotechnology company whose offering is organized as a single integrated R&D engine — the Genetic Medicines Product Engine — that generates and advances a wholly owned pipeline of one-time, precision AAV-based genetic medicines for severe neurological disorders. The platform combines high-throughput NGS screening with machine-learning-driven regulatory element optimization to engineer cell-type-selective AAV cassettes (e.g., REGABA for GABAergic neurons; NociPro for nociceptors; 3'UTR DRG de-targeting elements) and supports an internal GMP manufacturing ecosystem. The engine currently powers four named pipeline programs: the lead clinical-stage product ETX101 (AAV9 gene regulation therapy for SCN1A+ Dravet syndrome, advanced under the integrated POLARIS clinical program), the preclinical ETX301 (AAV9-miRNA for post-amputation neuroma pain, IND planned for 2027), a preclinical Angelman syndrome UBE3A-unsilencing program, and a preclinical Alzheimer's/tauopathies MAPT-knockdown program. Programs span monogenic (Dravet, Angelman) and common (chronic pain, tauopathies) neurological indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • ETX101 (for SCN1A+ Dravet Syndrome) Investigational AAV9-based, cell-selective gene regulation therapy for SCN1A+ Dravet syndrome. Delivered as a single intracerebroventricular (ICV) infusion, ETX101 uses an engineered transcription factor (eTF) under the GABAergic-selective REGABA promoter to upregulate endogenous SCN1A expression in inhibitory interneurons, restoring NaV1.1 sodium channel density. Designed for infants and young children aged 6 months to less than 4 years (pivotal Part 2) and ages 4 to 18 (Part 1B expansion). FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EMA Orphan designation.
  • ETX301 (for post-amputation neuroma pain) Investigational AAV9-based vectorized microRNA (miRNA) gene therapy for chronic neuropathic pain caused by post-amputation neuroma. Delivered via a single intrathecal injection using the NociPro nociceptor-selective promoter to knock down SCN9A (NaV1.7) in dorsal root ganglion nociceptive neurons. Targets the estimated 100,000 US patients with painful neuromas following lower limb amputation (~5,000 new cases annually). IND submission planned for 2027.
  • Angelman Syndrome Program (UBE3A Unsilencing) Preclinical one-time, vectorized miRNA-based gene therapy designed to unsilence the paternal UBE3A gene by targeting the UBE3A antisense transcript (UBE3A-ATS). Recent preclinical data showed ~57% increase in UBE3A expression and ~24% increase in UBE3A protein across cortex, hippocampus, and thalamus in non-human primates using a blood-brain-barrier-crossing AAV variant, with 60-day tolerability.
  • Alzheimer's Disease / Tauopathies Program Preclinical program applying Encoded's cell-selective AAV vector engineering to deliver miRNA-based knockdown of intracellular tau (MAPT), targeting Alzheimer's disease and related tauopathies. Addresses ~6 million people in the U.S. with Alzheimer's disease.
  • Genetic Medicines Product Engine End-to-end platform encompassing preclinical development, GMP manufacturing, multi-modal delivery, and clinical expertise for AAV-based gene therapies. Uses high-throughput NGS screening and machine-learning-driven regulatory element optimization to engineer cell-type-selective cassettes (REGABA for GABAergic neurons; NociPro for nociceptors; 3'UTR DRG de-targeting elements). Internal GMP manufacturing facility complemented by preferred CDMO relationships. Supports a wholly owned, internally developed pipeline of neurological gene therapies.
  • POLARIS Clinical Program (ENDEAVOR, EXPEDITION, WAYFINDER, ENVISION) Comprehensive ETX101 clinical development program comprising Phase 1/2 dose-escalation studies (ENDEAVOR Parts 1A and 1B, EXPEDITION, WAYFINDER), pivotal ENDEAVOR Part 2 (NCT05419492), the ENVISION natural history study (NCT04537832), the Dravet ENGAGE patient-focused initiative, and the ELUCIDATE biomarker discovery program. Conducted across the United States, United Kingdom, and Australia under FDA, MHRA, and TGA oversight.

Quantifiable outcome

  • ~76% median monthly countable seizure frequency (MCSF) reduction at DL3 (n=3) sustained from Week 5 through Week 52
  • +6 more outcomes

Companies that use Encoded Therapeutics

Customer profile

Named customers1 record

Ideal customer profiles3 records

Encoded Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Encoded Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered research collaboration, operational support and future potential.

  • External AAV capsid/BBB-crossing variant licensor (Angelman program)research collaborationOEM/ Whitelabel/ Licensing PartnerFor the Angelman syndrome program, Encoded paired its optimized miRNA candidate with an externally-developed blood-brain-barrier-crossing AAV variant to achieve widespread miRNA expression across disease-relevant brain regions in non-human primates (~57% increase in UBE3A expression). The specific external licensor is not named in the source material.
  • Preferred CDMO partnersoperational supportImplementation/ SI/ Consulting PartnerEncoded's GMP manufacturing ecosystem includes preferred CDMO relationships to complement its in-house GMP manufacturing facility. Encoded has invested in its own manufacturing capabilities since inception, with process development meeting current AAV commercial-scale requirements and infrastructure that meets GMP-scale requirements for multiple programs.
  • Industry co-development and licensing partnersfuture potentialStrategic or Co-development PartnerEncoded states it aims to continue developing its pipeline utilizing end-to-end capabilities and leveraging its research platform to broaden therapeutic reach "independently as well as through industry partnerships". Company is actively evaluating co-development and licensing opportunities via partnering@encoded.com.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Encoded Therapeutics competitors and assessment

Company assessment

Direct peers

  • Stoke Therapeutics: Direct competitor in SCN1A+ Dravet syndrome. Stoke is developing STK-001, an antisense oligonucleotide that upregulates SCN1A expression — the same target as Encoded's ETX101 — using a different modality (ASO vs. AAV gene therapy). Stoke is the most clinically advanced competitor in Dravet syndrome and serves the same patient population and physician community.
  • Taysha Gene Therapies: Clinical-stage AAV gene therapy company developing CNS-targeted genetic medicines. Notably, Encoded's Board Chairman Sean P. Nolan is also CEO of Taysha, creating direct leadership overlap. Both companies pursue AAV-based gene regulation therapies for severe neurological diseases with similar regulatory and manufacturing challenges.
  • Voyager Therapeutics: AAV gene therapy company developing CNS-targeted treatments for neurodegenerative diseases. Encoded's CEO Kartik Ramamoorthi previously served on the team that launched Voyager. Both companies use AAV capsids to deliver gene regulation payloads to specific CNS cell types, and compete for similar scientific talent and clinical sites.
  • Solid Biosciences: Clinical-stage AAV gene therapy company focused on Duchenne muscular dystrophy and CNS disorders. Similar to Encoded, Solid has faced safety setbacks, restructured operations, and rebuilt clinical programs — providing a comparable trajectory of a clinical-stage AAV gene therapy company navigating manufacturing scale-up and clinical development.
  • Passage Bio: Clinical-stage AAV gene therapy company developing CNS-targeted treatments for rare monogenic neurological diseases. Passage Bio's portfolio (e.g., GM1 gangliosidosis, Krabbe disease, frontotemporal dementia) overlaps with Encoded's CNS focus and shares similar scientific, manufacturing, and regulatory challenges in delivering AAV payloads to the brain.

Broad incumbents

  • AveXis (Novartis Gene Therapies): Established AAV gene therapy franchise within Novartis that developed and commercialized Zolgensma for spinal muscular atrophy — the benchmark one-time AAV therapy. Several Encoded executives (Sean Nolan, Andrew Stober) led AveXis through Zolgensma development, and AveXis represents the proven commercial and regulatory template for one-time AAV therapies in rare pediatric neurological disease.
  • Audentes Therapeutics (Astellas Gene Therapies): AAV gene therapy unit of Astellas developing treatments for rare neuromuscular diseases (e.g., AT132 for X-linked myotubular myopathy). Encoded CMO Salvador Rico led AT132 clinical development at Audentes. Operates the same AAV gene therapy model — internal manufacturing, rare disease focus, complex regulatory pathway — though with some high-profile safety setbacks.
  • Regenxbio: Established AAV gene therapy platform company that develops and licenses AAV capsid technology (including AAV9, used by Encoded for ETX101 and ETX301). Regenxbio is both a potential licensor/collaborator for Encoded and a competitor pursuing CNS and rare disease gene therapies using its proprietary NAV technology platform.
  • uniQure: Established gene therapy company with commercial AAV product (Hemgenix for hemophilia B) and CNS-directed AAV programs. Provides a comparable template for an AAV gene therapy company advancing from clinical development through commercial launch, including pricing, manufacturing, and reimbursement strategy for one-time therapies.
  • Pfizer (Gene Therapy Division): Large pharmaceutical company with a gene therapy portfolio that includes Beqvez (an AAV gene therapy for hemophilia B) and prior investments in AAV CNS programs. Represents a potential strategic acquirer or partner for Encoded's platform and pipeline, and a benchmark for large-pharma AAV manufacturing and commercialization capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Encoded Therapeutics social profiles

Digital presence

Encoded Therapeutics compliance and trust

Trust signal

Compliance8 records

Encoded Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Encoded Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Encoded Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Encoded Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Encoded Therapeutics

What does Encoded Therapeutics do?

Encoded Therapeutics is a clinical-stage biotechnology company developing one-time, AAV-based precision gene therapies that target the underlying genetic cause of severe neurological disorders. Its proprietary Genetic Medicines Product Engine uses high-throughput NGS screening of human regulatory elements combined with machine learning to design cell-selective cassettes (e.g., REGABA promoter, NociPro promoter, DRG de-targeting 3'UTRs) delivered via clinically validated AAV9 capsids. The lead investigational product, ETX101, is in pivotal development for SCN1A+ Dravet syndrome with five FDA designations (Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug) plus EMA Orphan designation.

Is Encoded Therapeutics a public or private company?

Encoded Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Encoded Therapeutics founded?

Encoded Therapeutics was founded in 2014. It employs 101 to 250 people.

Where is Encoded Therapeutics based?

Encoded Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Encoded Therapeutics make money?

One revenue line is on record: pre-revenue / Future one-time gene therapy product sales.

Who are Encoded Therapeutics's main competitors?

Direct peers on record are Stoke Therapeutics, Taysha Gene Therapies, Voyager Therapeutics, Solid Biosciences and Passage Bio. Broad incumbents are AveXis (Novartis Gene Therapies), Audentes Therapeutics (Astellas Gene Therapies), Regenxbio, uniQure and Pfizer (Gene Therapy Division).

Does Encoded Therapeutics have an API?

No public API is recorded for Encoded Therapeutics.

What industry is Encoded Therapeutics in?

Encoded Therapeutics's product category is Gene therapy for neurological disorders. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Encoded Therapeutics Raises $275 Million Series F To Advance Genetic Medicine For Dravet SyndromeEncoded Therapeutics raised $275 million in Series F financing to advance ETX101 through pivotal development for Dravet syndrome. The capital will support a pivotal study in infants and young children, an expansion study up to age 18, and commercial-scale manufacturing. The company also plans an IND submission for ETX301 in 2027.pharmaphorumEncoded raises $275m for Dravet therapy and other financingsEncoded Therapeutics raised $275 million to advance its Dravet syndrome gene therapy ETX101 into a pivotal trial, following phase 1/2 POLARIS data showing reduced seizure frequency. The funding will also support manufacturing scale-up and development of a second drug candidate, ETX301, for post-amputation pain.MarketScreenerRTW Biotech notes further investment in investee Encoded TherapeuticsRTW Biotech announced an additional investment in Encoded Therapeutics' USD275 million Series F financing. The investment, a further USD4.1 million, brings Encoded to 0.1% of RTW's net asset value. RTW shares rose 0.9% to USD2.38.YahooEncoded secures $275m for Dravet syndrome gene therapyEncoded Therapeutics raised $275M in a Series F round to advance its Dravet syndrome gene therapy ETX101. The therapy cut monthly seizures by up to 79% in a Phase I/II study. Proceeds will fund a pivotal trial and expansion study.Pharmaceutical TechnologyEncoded secures $275m for Dravet syndrome gene therapy - Pharmaceutical TechnologyEncoded Therapeutics raised $275m in a Series F round to advance its Dravet syndrome gene therapy ETX101. The funds will support a pivotal trial in infants and young children, with up to 79% seizure reduction reported in Phase I/II data. The company also plans to advance another asset, ETX301, toward an IND submission in 2027.BioSpaceEncoded raises $275M series F for Dravet syndrome gene therapyEncoded Therapeutics closed a $275 million series F round to advance its Dravet syndrome gene therapy ETX101. Phase 1/2 data showed median seizure reductions of 79% and 89% in patients. The company will use funds for a pivotal trial and expansion to children up to 18 years.The Pharma LetterEncoded raises $275 million to push Dravet gene therapy into pivotal testingEncoded Therapeutics closed a $275 million Series F financing to fund pivotal testing of ETX101, a gene therapy for Dravet syndrome. The round was co-led by GV and a healthcare fund, with participation from multiple investors. The company presented updated trial data at the European Epilepsy Congress.FinSMEsEncoded Therapeutics Raises $275M in Series F FundingEncoded Therapeutics raised $275M in Series F financing co-led by GV. The funds will support pivotal studies of ETX101 for Dravet syndrome, expansion studies, commercial scale-up of GMP manufacturing, and pipeline advancement including ETX301 toward a 2027 IND submission.AInvestEncoded's $275M Gene-Therapy Round You Can't Buy: Strong Data, a Small Market, and a 2027 VerdictEncoded Therapeutics closed a $275 million Series F round co-led by GV and an unnamed healthcare fund. The capital funds a pivotal trial of ETX101 for Dravet syndrome, with initial data showing an 83.5% seizure reduction in high-dose patients. The company's next data readout is expected in late 2027.VC News DailyEncoded Therapeutics Inks $275 Million in Series FEncoded Therapeutics closed a $275 million Series F financing. The round was co-led by GV and another healthcare fund, with participation from multiple investors including SoftBank Vision Fund and Venrock.